

Exhibit 161

(Filed Under Seal)

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

FOREST LABORATORIES, INC., *et al.*,

Plaintiffs,

vs.

COBALT LABORATORIES, INC., *et al.*,

Defendants.

C.A. No. 08-021 (GMS) (LPS) (Consolidated)

STIPULATION AND ORDER

The Court, upon the consent and request of Plaintiffs Forest Laboratories, Inc., Forest Laboratories Holdings Ltd., Merz Pharma GmbH & Co. KGaA and Merz Pharmaceuticals GmbH (collectively, "Plaintiffs") and Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited (collectively, "DRL"), hereby acknowledges the following Stipulation and issues the following Order.

STIPULATION

1. This Court has subject matter jurisdiction over this patent infringement action (the "Action") and personal jurisdiction over Plaintiffs and DRL. Venue is proper in this Court as to Plaintiffs and DRL.
2. In this Action, Plaintiffs have charged DRL with infringement of United States Patent No. 5,061,703 ("the '703 Patent") in connection with DRL's submission of Abbreviated New Drug Application ("ANDA") No. 90-048 directed to generic tablets containing 5 milligrams or 10 milligrams of memantine hydrochloride per tablet to the U.S. Food and Drug Administration ("FDA").
3. In response to Plaintiffs' charges of patent infringement, DRL has alleged certain defenses and counterclaims, including that the '703 Patent is invalid, unenforceable and/or not infringed by the generic tablet products containing 5 milligrams or 10 milligrams of memantine hydrochloride that are the subject of ANDA No. 90-048. No decision has been obtained by either party from this Court regarding these charges of infringement or these defenses and counterclaims.
4. DRL has not rebutted the statutory presumption that the '703 Patent is valid and enforceable in this Action. This admission is without prejudice to DRL's defenses and counterclaims that the '703 Patent is invalid, unenforceable and/or not infringed.

5. DRL admits that the submission of ANDA No. 90-048 to the FDA for the purpose of obtaining regulatory approval to engage in the commercial manufacture, use and/or sale of generic tablets containing 5 milligrams or 10 milligrams of memantine hydrochloride per tablet within the United States before the expiration of the '703 Patent was a technical act of infringement of that patent under 35 U.S.C. § 271(e)(2)(A). This admission is without prejudice to DRL's defenses and counterclaims that the '703 Patent is invalid, unenforceable and/or that the product described by ANDA No. 90-048 does not infringe that patent.

6. Both parties have agreed that all other claims, defenses and counterclaims set forth in Plaintiffs' and DRL's pleadings against each other, including the allegations and averments contained therein, should be dismissed, without prejudice.

ORDER

Accordingly, pursuant to the above Stipulation, and upon the consent and request of Plaintiffs and DRL, **IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:**

1. The filing of ANDA No. 90-048 was a technical act of infringement of the '703 Patent under 35 U.S.C. § 271(e)(2)(A). No decision of the Court has been obtained by either party regarding the presumptive validity and enforceability of the '703 Patent and/or whether the product described by ANDA No. 90-048 infringes that patent.

2. All other claims, defenses and counterclaims set forth in Plaintiffs' and DRL's pleadings against each other, including the allegations and averments contained therein, are hereby dismissed, without prejudice.

3. DRL, its officers, agents, servants, employees and attorneys, and those persons in active concert or participation with them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell or selling within the United States, or importing into the United States, the generic tablet products

containing 5 milligrams or 10 milligrams of memantine hydrochloride per tablet that are the subject of ANDA No. 90-048 during the life of the '703 Patent, including any extensions and pediatric exclusivities, absent a license agreement or other authorization by Plaintiffs, unless all of the asserted claims of the '703 Patent are found invalid or unenforceable by a court decision from which no appeal has been or can be taken, other than a petition for a writ of certiorari to the U.S. Supreme Court, or found not infringed by such a court decision which is relevant to the proposed use of the generic tablet products that are the subject of ANDA 90-048.

4. Plaintiffs and DRL each expressly waive any right to appeal or otherwise move for relief from this Stipulation And Order.

5. This Court retains jurisdiction over Plaintiffs and DRL for purposes of enforcing this Stipulation And Order.

6. This Stipulation And Order shall finally resolve this Action between Plaintiffs and DRL.

7. The Clerk of the Court is directed to enter this Stipulation And Order forthwith.

SO ORDERED:

This _____ day of _____, 2009

HONORABLE GREGORY M. SLEET
UNITED STATES DISTRICT JUDGE

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

POTTER ANDERSON & CORROON LLP

/s/ Maryellen Noreika

/s/ David E. Moore

Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3028)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com
Attorneys for Plaintiffs

Richard L. Horwitz (#2246)
David E. Moore (#3983)
Hercules Plaza, 6th Floor
1313 North Market Street
Wilmington, DE 19801
(302) 984-6000
rhorwitz@potteranderson.com
dmoore@potteranderson.com
*Attorneys for Dr. Reddy's Laboratories, Inc.
and Dr. Reddy's Laboratories, Ltd.*